메뉴 건너뛰기




Volumn 102, Issue 4, 2017, Pages 578-580

Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug–Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; GEMFIBROZIL; REPAGLINIDE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ABT-333; ANTIVIRUS AGENT; DRUG COMBINATION; GLUCURONIDE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; TICLOPIDINE; URACIL;

EID: 85018256225     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.699     Document Type: Note
Times cited : (11)

References (10)
  • 1
    • 84876483882 scopus 로고    scopus 로고
    • Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide
    • Varma, M.V. et al. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm. Res. 30, 1188–1199 (2013).
    • (2013) Pharm. Res. , vol.30 , pp. 1188-1199
    • Varma, M.V.1
  • 2
    • 29944446317 scopus 로고    scopus 로고
    • Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions
    • Ogilvie, B.W. et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191–197 (2006).
    • (2006) Drug Metab. Dispos. , vol.34 , pp. 191-197
    • Ogilvie, B.W.1
  • 3
    • 84983080825 scopus 로고    scopus 로고
    • Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers
    • Polepally, A.R. et al. Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin. Pharmacokinet. 55, 1003–1014 (2016).
    • (2016) Clin. Pharmacokinet. , vol.55 , pp. 1003-1014
    • Polepally, A.R.1
  • 4
    • 84953876603 scopus 로고    scopus 로고
    • Potential for a significant interaction between clopidogrel and dasabuvir
    • Stark, J.E. Potential for a significant interaction between clopidogrel and dasabuvir. Clin. Infect. Dis. 61, 134–135 (2015).
    • (2015) Clin. Infect. Dis. , vol.61 , pp. 134-135
    • Stark, J.E.1
  • 5
    • 84921630257 scopus 로고    scopus 로고
    • Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions
    • Tornio, A. et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498–507 (2014).
    • (2014) Clin. Pharmacol. Ther. , vol.96 , pp. 498-507
    • Tornio, A.1
  • 6
    • 84860007394 scopus 로고    scopus 로고
    • A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel
    • Floyd, J.S. et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther. 91, 896–904 (2012).
    • (2012) Clin. Pharmacol. Ther. , vol.91 , pp. 896-904
    • Floyd, J.S.1
  • 7
    • 85029326410 scopus 로고    scopus 로고
    • Physiologically based pharmacokinetic modeling suggests limited drug-drug interaction between clopidogrel and dasabuvir
    • &, (in review).
    • Shebley, M., Fu, W., Badri, P., Bow, D.A.J. & Fischer, V. Physiologically based pharmacokinetic modeling suggests limited drug-drug interaction between clopidogrel and dasabuvir. Clin. Pharmacol. Ther. (in review).
    • Clin. Pharmacol. Ther.
    • Shebley, M.1    Fu, W.2    Badri, P.3    Bow, D.A.J.4    Fischer, V.5
  • 8
    • 25844448609 scopus 로고    scopus 로고
    • Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin
    • Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 97, 249–256 (2005).
    • (2005) Basic Clin. Pharmacol. Toxicol. , vol.97 , pp. 249-256
    • Kajosaari, L.I.1    Laitila, J.2    Neuvonen, P.J.3    Backman, J.T.4
  • 9
    • 84989166290 scopus 로고    scopus 로고
    • Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information
    • Kim, S.J. et al. Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab. Dispos. 44, 1622–1632 (2016).
    • (2016) Drug Metab. Dispos. , vol.44 , pp. 1622-1632
    • Kim, S.J.1
  • 10
    • 84946407805 scopus 로고    scopus 로고
    • Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-beta-glucuronide
    • Kimoto, E., Li, R., Scialis, R.J., Lai, Y. & Varma, M.V. Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-beta-glucuronide. Mol. Pharm. 12, 3943–3952 (2015).
    • (2015) Mol. Pharm. , vol.12 , pp. 3943-3952
    • Kimoto, E.1    Li, R.2    Scialis, R.J.3    Lai, Y.4    Varma, M.V.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.